Complexes of rna and cationic peptides for transfection and for immunostimulation

Abstract

The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg) l ;(Lys) m ;(His) n ;(Orn) o ;(Xaa) x with the majority of residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

1 . A method of treating a subject having a disease, the method comprising administering an effective amount a pharmaceutical composition comprising mRNA encoding GLA to the subject. 
     
     
         2 . The method of  claim 1 , wherein the disease is Fabry disease. 
     
     
         3 . The method of  claim 1 , wherein the pharmaceutical composition is administered by intravenous injection or intramuscular injection. 
     
     
         4 . The method of  claim 1 , wherein the mRNA comprises a 5′ cap structure. 
     
     
         5 . The method of  claim 1 , wherein the mRNA additionally comprises a poly-A tail of 10 to 200 adenosine nucleotides. 
     
     
         6 . The method of  claim 1 , wherein the mRNA additionally comprises a poly-C tail of 10 to 200 cytosine nucleotides. 
     
     
         7 . The method of  claim 1 , wherein the mRNA further comprises a 5′ and/or a 3′ untranslated region (UTR). 
     
     
         8 . The method of  claim 1 , wherein the mRNA has been modified by introduction of a non-native nucleotide compared with a corresponding native mRNA nucleotide and/or by covalent coupling of the mRNA with a further chemical moiety. 
     
     
         9 . The method of  claim 1 , wherein the mRNA comprises a G/C content in the GLA coding region which is greater than the G/C content of a coding region of the native mRNA sequence encoding GLA. 
     
     
         10 . The method of  claim 1 , wherein the mRNA comprises an GLA coding sequence that is modified, compared with a native mRNA encoding GLA, such that at least one codon of the native mRNA which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is relatively frequent in the cell. 
     
     
         11 . The method of  claim 8 , wherein the mRNA comprises a chemical modification relative to a naturally occurring mRNA. 
     
     
         12 . The method of  claim 8 , wherein the mRNA comprises at least one nucleotide that is substituted with a nucleotide analog selected from the group consisting of: 2′-deoxy-2′-fluoro-oligoribonucleotide (2′-fluoro-2′-deoxycytidine-5′-triphosphate, 2′-fluoro-2′-deoxyuridine-5′-triphosphate), 2′-deoxy-2′-deamine oligoribonucleotide (2′-amino-2′-deoxycytidine-5′-triphosphate, 2′-amino-2′-deoxyuridine-5′-triphosphate), 2′-O-alkyl oligoribonucleotide, 2′-deoxy-2′-C-alkyl oligoribonucleotide (2′-O-methylcytidine-5′-triphosphate, 2′-methyluridine-5′-triphosphate), 2′-C-alkyl oligoribonucleotide, and isomers thereof (2′-aracytidine-5′-triphosphate, 2′-arauridine-5′-triphosphate), or azidotriphosphate (2′-azido-2′-deoxycytidine-5′-triphosphate, 2′-azido-2′-deoxyuridine-5′-triphosphate)4-thio-uridine-5′-(mono)phosphate, 2-Aminopurine-riboside-5′-(mono)phosphate, 5-Aminoallylcytidine-5′-(mono)phosphate, 5-Aminoallyluridine-5′-(mono)phosphate, 5-Bromocytidine-5′-(mono)phosphate, 5-Bromo-2′-deoxycytidine-5′-(mono)phosphate, 5-Bromouridine-5′-(mono)phosphate, 5-Bromo-2′-deoxyuridine-5′-(mono)phosphate, 5-Iodocytidine-5′-(mono)phosphate, 5-Iodo-2′-deoxycytidine-5′-(mono)phosphate, 5-Iodouridine-5′-(mono)phosphate, 5-Iodo-2′-deoxyuridine-5′-(mono)phosphate, 5-Propynyl-2′-deoxycytidine-5′-(mono)phosphate, 5-Propynyl-2′-deoxyuridine-5′-(mono)phosphate, 5-formylcytidine-5′-(mono)phosphate, 5,2′-O-dimethylcytidine-5′-(mono)phosphate, 5-hydroxymethylcytidine-5′-(mono)phosphate, 5-formyl-2′-O-methylcytidine-5′-(mono)phosphate, 5,2′-O-dimethyluridine-5′-(mono)phosphate, 5-methyl-2-thiouridine-5′-(mono)phosphate, 5-hydroxyuridine-5′-(mono)phosphate, 5-methoxyuridine-5′-(mono)phosphate, uridine 5-oxyacetic acid-5′-(mono)phosphate, uridine 5-oxyacetic acid methyl ester-5′-(mono)phosphate, 5-(carboxyhydroxymethyl)uridine-5′-(mono)phosphate, 5-(carboxyhydroxymethyl)uridine methyl ester-5′-(mono)phosphate, 5-methoxycarbonylmethyluridine-5′-(mono)phosphate, 5-methoxycarbonylmethyl-2 ′-O-methyluridine-5′-(mono)phosphate, 5-methoxycarbonylmethyl-2-thiouridine-5′-(mono)phosphate, 5-aminomethyl-2-thiouridine-5′-(mono)phosphate, 5-methylaminomethyluridine-5′-(mono)phosphate, 5-methylaminomethyl-2-thiouridine-5′-(mono)phosphate, 5-methylaminomethyl-2-selenouridine-5′-(mono)phosphate, 5-carbamoylmethyluridine-5′-(mono)phosphate, 5-carbamoylmethyl-2′-O-methyluridine-5′-(mono)phosphate, 5-carboxymethylaminomethyluridine-5′-(mono)phosphate, 5-carboxymethylaminomethyl-2′-O-methyluridine-5′-(mono)phosphate, 5-carboxymethylaminomethyl-2-thiouridine-5′-(mono)phosphate, 5-carboxymethyluridine-5′-(mono)phosphate, 5-methyldihydrouridine-5 ′-(mono)phosphate, 5-taurinomethyluridine-5′-(mono)phosphate, 5-taurinomethyl-2-thiouridine-5′-(mono)phosphate, 5-(isopentenylaminomethyl)uridine-5′-(mono)phosphate, 5-(isopentenylaminomethyl)-2-thiouridine-5′-(mono)phosphate, 5-(isopentenylaminomethyl)-2′-O-methyluridine-5′-(mono)phosphate, 6-Azacytidine-5′-(mono)phosphate, 7-Deazaadenosine-5′-(mono)phosphate, 7-Deazaguanosine-5′-(mono)phosphate, 8-Azaadenosine-5′-(mono)phosphate, 8-Azidoadenosine-5′-(mono)phosphate, Pseudouridine-5′-(mono)phosphate, 2′-Amino-2′-deoxycytidine-(mono)phosphate, 2′-Fluorothymidine-5′-(mono)phosphate, inosine-5′-(mono)phosphate, and 2′-O-Methyl-inosine-5′-(mono)phosphate. 
     
     
         13 . The method of  claim 8 , wherein the mRNA comprises at least one nucleotide that is substituted with a nucleotide analog selected from the group consisting of: 2-amino-6-chloropurineriboside-5′-triphosphate, 2-aminoadenosine-5′-triphosphate, 2-thiocytidine-5′-triphosphate, 2-thiouridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5-aminoallylcytidine-5′-triphosphate, 5-aminoallyluridine-5′-triphosphate, 5-bromocytidine-5′-triphosphate, 5-bromouridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate, 5-iodouridine-5′-triphosphate, 5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate, 6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate, 6-chloropurineriboside-5′-triphosphate, 7-deazaadenosine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate, 8-azaadenosine-5′-triphosphate, 8-azidoadenosine-5′-triphosphate, benzimidazole-riboside-5′-triphosphate, N1-methyladenosine-5′-triphosphate, N1-methylguanosine-5′-triphosphate, N6-methyladenosine-5′-triphosphate, O6-methylguanosine-5′-triphosphate, pseudouridine-5′-triphosphate, puromycin-5′-triphosphate, and xanthosine-5′-triphosphate. 
     
     
         14 . The method of  claim 13 , wherein the nucleotide analog is chosen from the group consisting of: 5-methylcytidine 5′-triphosphate and pseudouridine 5′-triphosphate. 
     
     
         15 . The method of  claim 1 , wherein the pharmaceutical composition further comprises a cationic polymer and/or cationic lipid. 
     
     
         16 . The method  claim 15 , wherein the cationic polymer is a cationic peptide or polypeptide. 
     
     
         17 . The method  claim 15 , wherein the mRNA is provided in complex with the cationic polymer and/or cationic lipid. 
     
     
         18 . A pharmaceutical composition comprising an isolated mRNA comprising a sequence encoding GLA, wherein:
 (i) the sequence encoding GLA is linked to a heterologous 5′ and/or 3′ untranslated region (UTR); and/or   (ii) the pharmaceutical composition further comprises a cationic polymer and/or cationic lipid.   
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the mRNA is modified by introduction of a non-native nucleotide compared with a native mRNA sequence and/or by covalent coupling of the mRNA with a further chemical moiety.